Efficacy and safety of G-CSF prophylaxis in patients with extensive-stage small cell lung cancer receiving chemoimmunotherapy-Reference-Cited by-同舟云学术

Efficacy and safety of G-CSF prophylaxis in patients with extensive-stage small cell lung cancer receiving chemoimmunotherapy

Published:2024-07-23 Issue:11 Volume:25 Page:1555-1563
ISSN:1465-6566
Container-title:Expert Opinion on Pharmacotherapy
language:en
Short-container-title:Expert Opinion on Pharmacotherapy

Author:

Ilhan Yusuf¹^ORCID,Ucar Gokhan²,Baser Mehmet Nuri³,Guzel Halil Goksel⁴,Efil Safa Can²^ORCID,Demir Bilgin³,Ercan Uzundal Duygu⁵,Karacelik Tuba⁶,Sever Nadiye⁷,Balcik Onur Yazdan⁸,Arvas Hayati⁹,Karadag Ibrahim¹⁰,Kadioglu Ahmet¹¹,Ekinci Ömer Burak¹²,Karacin Cengiz¹¹,Urakci Zuhat⁹,Kostek Osman⁷,Karakurt Eryilmaz Melek⁶,Yazici Ozan⁵,Sendur Mehmet Ali Nahit²,Ozturk Banu⁴,Uncu Dogan²,Ergun Yakup¹^ORCID

Affiliation:

1. Department of Medical Oncology, Antalya City Hospital, Antalya, Turkey

2. Department of Medical Oncology, Ankara Bilkent City Hospital, Ankara, Turkey

3. Department of Medical Oncology, Adnan Menderes University, Aydın, Turkey

4. Antalya Education and Research Hospital, Department of Medical Oncology, Health Sciences University, Antalya, Turkey

5. Faculty of Medicine, Department of Medical Oncology, Gazi University, Ankara, Turkey

6. Faculty of Medicine, Department of Medical Oncology, Necmettin Erbakan University, Konya, Turkey

7. Faculty of Medicine, Department of Medical Oncology, Marmara University, Istanbul, Turkey

8. Department of Medical Oncology, Mardin Training and Research Hospital, Mardin, Turkey

9. Faculty of Medicine, Department of Medical Oncology, Dicle University, Diyarbakır, Turkey

10. Erol Olcok Education and Research Hospital, Department of Medical Oncology, Hitit University, Corum, Turkey

11. Department of Medical Oncology, University of Health Sciences, Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Ankara, Turkey

12. Department of Medical Oncology, Cemil Tascioglu City Hospital, Istanbul, Turkey

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/14656566.2024.2391007

Reference21 articles.

1. Cancer statistics, 2022

2. Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions

3. Current standards for clinical management of small cell lung cancer

4. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

5. Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial